A Study To Assess A Novel Form Of Cataract Treatment Using The Non-Invasive REVISYON Proof-Of-Concept Device

NCT04569318 | Completed

• 1 other identifier: EB-14-LAT
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

Single arm proof-of-concept trial to evaluate the safety and efficacy of the REVISYON PoC Device in the treatment of cataract.

Conditions

Cataract

Outcome Measures

Primary Outcomes (2)

• Safety: assessed by changes in the Local Ocular Tolerability (LOT) Visual Analogue Scale (VAS)

  Assessment of safety defined as changes in the LOT VAS. A self-administered 7-item (foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia) 100 mm VAS on which 0 means no symptoms and 100 means the worst possible discomfort. VAS Ocular Tolerability Overall score is the mean of all VAS Ocular Tolerability symptom scores per visit per eye

  20 weeks

• Efficacy: Cataract Grade

  Assessment of efficacy, defined as treating cataract assessed using Lens Opacities Classification System (LOCS) III. Higher scores mean a worse outcome.

  5 weeks

Secondary Outcomes (4)

• Change in cataract severity

  5 weeks

• Change in visual acuity

  5 weeks

• Change in light scatter

  5 weeks

• Change in functional impairment due to cataract

  5 weeks

Study Arms (1)

Treatment Arm

EXPERIMENTAL

Treatment with treatment beam.

Device: Treatment Beam

Interventions

Treatment Beam DEVICE

One of the subject's eyes will be treated with the treatment beam (20mW) up to 8 times for 15 minutes.

Treatment Arm

Eligibility Criteria

• Age: 55 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject diagnosed with nuclear sclerotic (NS) lens opacities cataract, LOCS III grade 1 to 3 (moderate), as confirmed by the Investigator
• Subject aged between 55 and 85 years of age (inclusive) at the time of consent
• Best corrected visual acuity (BCVA) of 0.3 or worse due to cataract only
• Subject whom the medical health history has been reviewed by the Investigator and medical records do not contraindicate the participation to the study
• Subject who is judged suitable for the study after ophthalmic examination carried out by the Investigator
• Be able and willing to follow instructions, including participation in all study assessments and visits, according to the opinion of the investigator - including being able to sit upright for at least 20 mins (duration of the treatment)

You may not qualify if:

• Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalised by court or official order, or in a dependency relationship with sponsor, testing centre or investigator
• Subject who had been clinically diagnosed with any eye diseases which may impact upon the treatment, or the subject's ability to be assessed after treatment
• Subject with shallow anterior chamber
• Subject who have had a fluorescence angiogram or any use of fluorescein within the last 3 days
• Subject presenting eye infection or eye damage in either eye
• Subject routinely using contact lenses
• Planned replacement of crystalline lens with intraocular lens (IOL) implant within the planned study period
• Any condition which could interfere with the subject's ability to comply with the study including participation in all study assessments and visits.
• Subject who had undergone a treatment using photodynamic drugs within the last 30 days. (Including but not limited to methylene blue, toluidine blue, Visudyne®, Foscan, Photofrin or 5-aminolevulinic acid/ALA)
• Subject diagnosed with any other health condition which, in the opinion of the Investigator, would pose a safety risk to the subject by participating in the study, or may interfere with or jeopardise the study evaluation, procedures or completion
• Subject currently receiving treatment in another investigational study or has completed another investigational study within the last 30 days
• Females who are pregnant or lactating
• Females who are of childbearing potential (menses within the last 12 months) and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable contraceptive precautions may be included.

Sponsors & Collaborators

• Edinburgh Biosciences Ltd: lead
• Onorach Clinical: collaborator

Study Sites (1)

Dr.Solomatina Acu Centrs

Riga, LV-1050, Latvia

Location

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens Diseases; Eye Diseases

Study Officials

• Chief Executive

  Edinburgh Biosciences Ltd

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: Unmasked
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single arm interventional study

Study Record Dates

• First Submitted: September 17, 2020
• First Posted: September 29, 2020
• Study Start: October 19, 2020
• Primary Completion: August 19, 2021
• Study Completion: September 9, 2021
• Last Updated: November 24, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

LA (1)